Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Myers Squibb (NYSE:BMY) or Johnson & Johnson (NYSE:JNJ) the better choice today? Bristol-Myers Squibb focuses on developing innovative medicines for serious diseases, while Johnson & Johnson combines a pharmaceutical powerhouse with a massive medical technology division. Both companies face unique regulatory hurdles and patent cycles, making their outlooks a study in risk versus stability. Bristol-Myers Squibb focuses on specialized biopharmaceutical products, particularly in the fields of oncology, hematology, and cardiovascular health. The company distributes its medicines through wholesalers and specialty pharmacies, while also utilizing direct-to-patient offerings. Key partnerships with companies like BioNTech (NASDAQ:BNTX) and the U.S. Government help support its global reach and development efforts. Continue reading